Protothecal peritonitis in child after bone marrow transplantation: case report and literature review of paediatric cases

T. Sykora¹, J. Horakova¹, D. Buzzasyova², M. Sladekova³, M. Poczova³ and S. Sufliarska¹
¹) Department of Paediatric Haematology and Oncology, Haematopoietic Stem Cell Transplantation Unit, 2) Department of Paediatric Anaesthesiology and Intensive Medicine, Comenius University Children’s Hospital, and 3) Department of Mycology, HPL Ltd., Bratislava, Slovakia

Abstract

The case presented here illustrates a protothecal infection caused by Prototheca wickerhamii in a paediatric haematopoietic stem cell recipient followed by a review of the literature of all 13 paediatric cases published since 1980. Protothecosis is a rare disease caused by algae, not described in this setting before. Infection was proven additionally post-mortem from peritoneal dialysis fluid. Even though no death of a paediatric patient due to this infection has been reported and the mortality rate associated with protothecosis is low, our patient died from multiorgan failure as a result of numerous post-transplant complications and a strain of cultivated alga that was highly resistant to antifungal agents. Prototheca spp. show various susceptibility profiles, and there is no direct correlation between in vitro activity and clinical response. There are different treatment regimens described but there are no clear published guidelines of specific therapy of protothecosis. Paediatric cases were successfully treated mostly with amphotericin B and azoles. As the number of immunocompromised patients increases, it is necessary to think more about unusual pathogens such as Prototheca.

Keywords: Bone marrow transplantation, child, peritoneal dialysate, Prototheca wickerhamii, protothecosis

Article published online: 14 September 2014

New Microbe and New Infect 2014; 2: 156–160

Corresponding author: T. Sykora, Department of Paediatric Haematology and Oncology, Haematopoietic Stem Cell Transplantation Unit, Comenius University Children’s Hospital, Bratislava, Slovakia
E-mail: tomas.sykora@dfnsp.sk

Case Report

A 3-year-old boy with Philadelphia-chromosome-positive, high-risk acute lymphoblastic leukaemia achieved the first complete remission and underwent allogeneic stem cell transplantation (SCT) from a 10/10 HLA-matched unrelated donor. His conditioning regimen consisted of Fludarabine/Treosulphan/Thiotepa and anti-thymocyte globulin + cyclosporin A as a graft-versus-host disease (GVHD) prophylaxis. The graft was infused after erythrodepletion due to ABO incompatibility.

Day +1 after SCT he developed febrile neutropenia. Aetiology of this febrile episode was later identified from a blood culture as Klebsiella pneumoniae and it was treated according to the antibiotic sensitivity tests. In the peri-transplant period he developed a severe veno-occlusive liver disease with high bilirubin blood level, body fluid retention and ascites with the necessity for abdominal drain insertion. Later, anuria and respiratory failure developed and the patient was transferred to the intensive care unit for mechanical ventilation and peritoneal dialysis. Bilirubin blood levels continued to rise up to 857 μmol/L (50.1 mg/dL), a molecular adsorbent recirculation system was used four times. On neutrophil engraftment day +21 the patient’s condition had improved—laboratory inflammation markers were decreased as well as fever. On day +26, the intestinal form of GVHD developed with massive intestinal bleeding. Candida fabianii and multiresistant Staphylococcus epidermidis and Enterococcus faecalis were identified as microbial agents causing other concomitant infections (Fig. 1).

Despite 39 days of peritoneal dialysis, the kidney function of the patient did not improve and another febrile episode developed with increased laboratory inflammation markers.

© 2014 The Authors. New Microbes and New Infections published by John Wiley & Sons Ltd on behalf of the European Society of Clinical Microbiology and Infectious Disease.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Blood cultures and dialysate culture showed multiresistant *Stenotrophomonas maltophilia* to be the cause of sepsis. Despite intensive and multidisciplinary care the patient died on day +55 after SCT. In addition, the result of dialysate culture revealed a very rare *Prototheca wickerhamii*. Autopsy was not performed.

**Discussion**

*Prototheca* spp. are ubiquitous chlorophyllous algae belonging to the Chlorophyceae. Besides various environmental niches, *Prototheca* spp. have been found colonizing the human skin, fingernails and respiratory and digestive systems [1]. It is not a common hospital-borne infection. Hospital-acquired cases have been associated with surgery and orthopaedic procedures, but human-to-human transmission has not been reported [1]. The source of the infection in this case is unknown.

Five species of *Prototheca* have been distinguished, of which only two—*P. wickerhamii* and *Prototheca zopfii*—are described as pathogenic in humans [1]. In the present case white and pale cream-coloured yeast-like colonies were grown on Sabouraud dextrose agar with antibiotics after 5 days of incubation at 30°C. Direct microscopy showed large Gram-positive cells of various sizes resembling yeast-like formations but budding was absent (Fig. 2). Further micromorphological and biochemical description was made with identification of the strain as *P. wickerhamii*.

According to animal experiments, *Prototheca* spp. seem to have low virulence, overall their pathogenicity is moderate and protothecosis is considered a rare opportunistic infection [2,3].
| Patient no. | Age/sex  | Medical history                  | Site/organ involvement | Diagnosis                  | Treatment                  | Outcome | Reference                              |
|------------|----------|----------------------------------|------------------------|----------------------------|----------------------------|---------|----------------------------------------|
| 1          | 7 years/M| Hodgkin’s lymphoma               | Catheter tip           | Culture P. wickerhami      | Catheter removal            | Cure     | Leimann et al., 2004 (Heney et al., 1991) |
| 2          | 17 years/F| Surgery, ganglion removal        | Hand abscess           | Culture P. wickerhami      | Multiple excisions          | Cure     | Leimann et al., 2004 (Iacoviello et al., 1992 Holcomb, 1981) |
| 3          | 8 months/| Unlisted                         | Gastroenteritis        | Culture P. wickerhami      | None                       | Unlisted | Leimann et al., 2004 (Iacoviello et al., 1992) |
| 4          | 6 years/F| Unlisted                         | Vulva                  | Culture P. wickerhami      | Gentian violet, steroids    | Cure     | Casal, 1983*                            |
| 5          | 5 years/F| Unlisted                         | Upper lip              | Culture P. wickerhami      | Ketoconazole               | Good response | Leimann et al., 2004 (Iacoviello et al., 1992) |
| 6          | 15 years/M| Unlisted                        | Small intestine, liver| Histopathology and culture P. wickerhami | Am B + fluconazole | Unlisted | Leimann et al., 2004 (Ravisse et al., 1993 Matsuda, 1991)* |
| 7          | 13 years/M| Anaemia                          | Small intestine + lymph nodes | Histopathology and culture P. wickerhami | Am B | Unlisted | Leimann et al., 2004 (Ravisse et al., 1993 Matsuda, 1991)* |
| 8          | 78 days/M| Very low birthweight             | Endocarditis           | Histopathology and culture P. wickerhami | Resection of atrium mass | Cure     | Leimann et al., 2004 (Buendra et al., 1999) |
| 9          | 10 years/M| Combined immunodeficiency       | Skin + olecranian bursitis | Culture P. wickerhami      | Am B + itraconazole IVIG   | Good response | Mathew et al., 2010                      |
| 10         | 6 months/M| Congenital hydrocephalus        | Central nervous system | Microscopy and molecular identification | Ketoconazole + Flucconazole | Cure     | Zak et al., 2012                        |
| 11         | 14 years/M| Unlisted                        | Skin                   | Microscopy and culture Prototheca spp. | Itraconazole               | Cure     | Kalsey et al., 2012                     |
| 12         | 4 years/F| Liver transplantation,           | Lungs                  | Culture P. wickerhami      | Am B                      | Cure     | Tan et al., 2013                        |
| 13         | 2 years/F| Submental and foot abscess      | Skin                   | Microscopy identification  | Am B + gentamicin Itraconazole | Cure     | Tello-Zavala et al., 2013               |
| 14         | 3 years/M| ALL Ph +, MUD BMT, multiorgan failure | Peritoneal dialysate  | Culture P. wickerhami      | None                      | Death    | Here presented                        |

*References from Table 1: Leimann et al., 2004 [4]; Heney et al., 1991 [8]; Iacoviello et al., 1992 [9]; Buendra et al., 1998 [11]; Mathew et al., 2010 [12]; Kalsey et al., 2012 [13]; Tello-Zavala et al., 2013 [16]; Am B, amphotericin B; ALL Ph +, positive high-risk acute lymphoblastic leukaemia; IVIG, intravenous immunoglobulin; MUD BMT, unrelated matched donor bone marrow transplantation.

*Cases mentioned and referred to in Iacoviello’s review (1992).

*Cases mentioned and referred to in Ravisse’s review (1993).
TABLE 2. Minimal inhibition concentration profile of Prototheca wickerhamii strain cultivated in the present case.

| Antifungal agent        | Dosage (mg/L) | Susceptibility       |
|------------------------|---------------|----------------------|
| Voriconazole           | 32.0          | Resistant            |
| Posaconazole           | 2.0           | Susceptible only to higher dosage |
| Amphotericin B         | 0.094         | Susceptible          |
| Fluconazole            | 256.0         | Resistant            |
| Itraconazole           | 32.0          | Resistant            |
| Echinocandins (micafungin, anidulafungin, caspofungin) | 32.0 | Resistant            |

According to the clinical presentation, there are three distinguished clinical forms known—cutaneous infection, bursitis and systemic infection. The most common are cutaneous infection and olecranon bursitis; systemic dissemination or organ involvement represents only 10% of all reported infections [4]. Previous review studies suggested a 2.2% attributable mortality rate, which represents a lower number compared with candidaemia, but individual outcome still depends on the history and clinical context of each patient [5]. Among all patients with cancer and protothecosis, overall mortality was 54% and attributable mortality was 14% [6].

Patients who are immunocompromised due to steroid use or who have underlying haematological/solid malignancy or AIDS have a higher risk of protothecosis.

More than 120 cases of protothecosis have been reported and it is believed that a much greater number of cases are unreported, perhaps because of morphological confusion with other microbes such as *Lacazia lobii*, *Coccidi desimmitis*, *Histoplasma duboisii*, *Blastomyces dermatitis* or *Pneumocystis jirovecii* [7].

Protothecosis in children mostly presents as infections involving various organs. From the 13 cases reported five were cutaneous, with or without olecranon bursitis, one was a catheter-related infection and the rest had other organ involvement (Table 1). Generally, *Prototheca* spp. show various susceptibility profiles, and there is no direct correlation between in vitro activity and clinical response [1]. There are no published guidelines of specific treatments for protothecosis. Algae are susceptible to amphotericin B and most of them were resistant to 5-flucytosine, fluconazole and itraconazole [5]. In contrast to this, voriconazole shows superior activity against *P. wickerhamii* [1]. In the case described here, the *P. wickerhamii* strain was fully susceptible only to amphotericin B, voriconazole was not effective (Table 2). Paediatric cases were successfully treated mostly by amphotericin B and azoles (Table 1). From review papers it can generally be concluded that most failures are associated with monotherapy by azoles [1]. The therapeutic response of paediatric patients to amphotericin B treatment is very good, even though the optimal dosage and duration of an antifungal therapy are unknown. The only death of a child with protothecosis reported is our present patient. Antifungal treatment and prophylaxis of our patient followed the SCT guidelines using micafungin antymycotic prophylaxis. Changes of anti-infective agents followed the recommendations of the European Society for Blood and Marrow Transplantation guidelines according to the current clinical status and microbial finding in the patient (Fig. 1). However, the anti-infective management was very challenging because of the kidney failure and other post-transplantation complications.

Protothecosis usually runs with other co-pathogens such as cytomegalovirus, herpes simplex virus, *Staphylococcus aureus*, *Enterococcus faecalis*, *Pseudomonas aeruginosa*, *Klebsiella pneumoniae*, *Escherichia coli*, *Cryptococcus* spp., *Candida glabrata* and *Aspergillus* spp. [1]. In the present case different co-pathogens were identified: Gram-negative bacterium *Stenotrophomonas maltophilia* and *Candida fabianii* (Fig. 1). Cytomegalovirus, Epstein–Barr virus, adenovirus and BK virus infections repeatedly tested negative on PCR. Besides viruses, mannann, anti-mannan and galactomannan antigen testing was run for complete mycology follow up. Microbiological tests were performed routinely every 3–4 days; collection of specimens was performed in sterile conditions. Infection developed on caspofungin, meropenem and acyclovir. Amphotericin B appears to be the most effective drug for systemic protothecosis, although it has been reported to be ineffective in some cases. So far it is recommended as the first-line therapy in cases of dissemination and for patients who are severely immunocompromised, or have other underlying illness [17]. This recommendation was irrelevant for our patient because of the kidney failure that did not improve.

Duration of microbial identification in our settings is approximately 4 days. The results of the cultures from the peritoneal dialysate were obtained after the patient had died. It is evident that the unstable and critical condition of the patient played a key role in his death and the protothecal infection was only a contributory factor. Regarding the source of infection, the reported data of protothecosis in patients with long-lasting peritoneal dialysis showed that the catheter was infected. In the case described here, the peritoneal catheter was replaced 1–2 days before death, due to its malfunction and clogging with blood coagula. We have no evidence of contaminated surgical equipment during the handling procedure. Previous peritoneal dialysates tested negative; this was the only positive specimen. After the identification of *P. wickerhamii*, a sample of the alga was deposited in the mycology laboratory archives.

According to published data, this is the first reported case of protothecosis in a paediatric bone marrow transplantation.
recipient. There is a rising probability of infection by less common and more atypical infectious organisms. *Prototheca* is a rare pathogen and so is not usually suspected. As the number of immunocompromised patients increases, it is necessary to think more of unusual pathogens when it comes to diagnosis of infectious complications during treatment.

**Acknowledgements**

The authors would like to thank Zuzana Kizekova, Ivana Bodova, Peter Svec, Oksana Fabri, Alica Chocholova, Jaroslava Adamicakova and Dominika Tanuskova, to colleagues who work at the Department of Paediatric Anaesthesiology and Intensive Medicine, Comenius University Children’s Hospital, Bratislava, Slovakia and to staff who work at Haematopoietic Stem Cell Transplantation Unit for the professional co-operation.

**Conflict of Interest**

None declared.

**References**

1. Lass-Florl C, Mayr A. Human protothecosis. *Clin Microbiol Rev* 2007; 20: 230–242.
2. Phair J, Williams J, Bassaris H, Zeiss C, Morlock B. Phagocytosis and algalicidal activity of human polymorphonuclear neutrophils against *Prototheca wickerhamii*. *J Infect Dis* 1981; 144: 72–77.
3. Huerre M, Ravisse P, Solomon H et al. Human protothecosis and environment. *Bull Soc Pathol Exot* 1993; 86: 484–488.
4. Leimann BCQ, Monteiro PCF, Lazera M, Candanoza ER, Wanke B. Protothecosis—case report and literature review. *Med Mycol* 2004; 42: 95–106.
5. Krémery V Jr. Systemic chlorellosis, an emerging infection in human caused by algae. *Int J Antimicrob Agents* 2000; 15: 235–237.
6. Torres HA, Bodey GP, Tarrand JJ, Kontoyiannis DP. Protothecosis in patients with cancer: case series and literature review. *Clin Microbiol Infect* 2003; 9: 786–792.
7. Lacaz CS, Porto E, Matins JEC, Heins-Vaccari EM, Melo NT. Tratado de micologia medica, 9th edn. Sao Paulo: Sarvier, 2002.
8. Heney C, Grief M, Davis V. Hickman catheter-related protothecal algemia in an immunocompromised child. *J Infect Dis* 1991; 163: 930–933.
9. Iacovello VR, DeGirolami PC, Lucarini J, Sutker K, Williams ME, Wanke CA. Protothecosis complicating prolonged endotracheal intubation: case report and literature reviews. *Clin Infect Dis* 1992; 15: 959–967.
10. Ravisse P, de Bievre C, Campos Magalhaes M, Ramos I, Huerre M. Protothecosis cutanée traitée avec succès par itraconazole: nouveau cas et revue générale des protothecoses humaines. *J Mycol Med* 1993; 3: 84–94.
11. Buendra J, Navarro G, Hojales A, Torues A. Protothecal endocarditis in neonate. *Pediatr Infect Dis J* 1999; 22: 13–14.
12. Mathew LG, Pulimood S, Thomas M, Acharya MA, Raj PM, Mathews MS. Disseminated protothecosis. *Indian J Pediatr* 2012; 77: 198–199.
13. Zak I, Jagielski T, Kwiatkowski S, Bielecki J. *Prototheca wickerhamii* as a cause of neuroinfection in a child with congenital hydrocephalus. First case of human protothecosis in Poland. *J Diagn Microbiol* 2012; 74: 186–189.
14. Kalsy J, Malhotra S, Chahal KS, Malhotra SK. Rare case report of localized cutaneous protothecosis in an immunocompetent male. *EDOJ* 2012; 8: 9.
15. Tan RMR, Aw MM, Quah SH, Chan SM. Pulmonary protothecosis in a pediatric liver transplant patient. *J Pediatric Infect Dis Soc* 2013; 2: 1–4.
16. Tello Zavala MC, Mercado-Lara A, Gómez-Hernández N, Recio-Martínez V. Disseminated protothecosis in a Mexican child. *Pediatr Infect Dis J* 2013; 32: e476–7.
17. Kantrow S, Boyd A. Protothecosis. *Dermatol Clin* 2003; 21: 249–255.